Validation and clinical utility of OMGRate and MG-QOL15 in evaluating symptoms and quality of life in Chinese patients with ocular myasthenia gravis - Quiz - MDSpire

Validation and clinical utility of OMGRate and MG-QOL15 in evaluating symptoms and quality of life in Chinese patients with ocular myasthenia gravis

  • By

  • Ting Tang

  • Qiwen Feng

  • Youran Cai

  • Yuying Dong

  • Jian Chen

  • Rijia Zhang

  • Qing Zhou

  • May 22, 2026

  • 0 min

Share

Original Source(s)

Validation and clinical utility of OMGRate and MG-QOL15 in evaluating symptoms and quality of life in Chinese patients with ocular myasthenia gravis

  • by Ting Tang, Qiwen Feng, Youran Cai, Yuying Dong, Jian Chen, Rijia Zhang, Qing Zhou

  • May 22, 2026

Related Content

New Target for Uveitis Therapy

Could targeting cGAS-STING represent a new treatment avenue for uveitis?

  • May 21, 2026

  • 3 min
Retinal Age as Disease Biomarker

Fundus-based AI screening can indicate “retinal age” of patients, as well as flag systemic disease risks, says new study

  • May 27, 2026

  • 3 min
FOXC1 Duplications Linked to Early-Onset Glaucoma

FOXC1 duplications were the second most common monogenic finding among genetically solved juvenile open-angle glaucoma cases in one registry, supporting the use of copy-number variant analysis in early-onset glaucoma testing.